Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

被引：13
|
作者：
Devlies, Wout [1 ,2 ]
Eckstein, Markus [3 ]
Cimadamore, Alessia [4 ]
Devos, Gaetan [1 ]
Moris, Lisa [1 ,2 ]
van den Broeck, Thomas [1 ]
Montironi, Rodolfo [4 ]
Joniau, Steven [1 ]
Claessens, Frank [2 ]
Gevaert, Thomas [5 ]
机构：
[1] Univ Hosp Leuven, Dept Urol, B-3000 Leuven, Belgium
[2] Katholieke Univ Leuven, Lab Mol Endocrinol, B-3000 Leuven, Belgium
[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany
[4] Polytech Univ theMarche Reg, United Hosp, Sch Med, Sect Pathol Anat, I-60121 Ancona, Italy
[5] Univ Hosp Leuven, Dept Pathol, B-3000 Leuven, Belgium
来源：
CELLS | 2020年 / 9卷 / 11期
关键词：
prostate cancer; biomarker; targeted therapies; histology; mCRPC; androgen receptor; ANDROGEN-DEPRIVATION THERAPY; CIRCULATING TUMOR-CELLS; POZ PROTEIN SPOP; EMERGING MECHANISMS; RECEPTOR; EXPRESSION; MUTATIONS; GENE; TMPRSS2-ERG; INHIBITORS;
D O I：
10.3390/cells9112494
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
引用
收藏
页码：1 / 13
页数：13
相关论文
共 50 条
  • [41] The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer
    Onstenk, Wendy
    de Kiaver, Willemijn
    de Wit, Ronald
    Lolkema, Martijn
    Foekens, John
    Sleijfer, Stefan
    CANCER TREATMENT REVIEWS, 2016, 46 : 42 - 50
  • [42] Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
    de Kruijff, Ingeborg E.
    Sieuwerts, Anieta M.
    Onstenk, Wendy
    Kraan, Jaco
    Smid, Marcel
    Van, Mai N.
    van der Vlugt-Daane, Michelle
    Oomen-de Hoop, Esther
    Mathijssen, Ron H. J.
    Lolkema, Martijn P.
    de Wit, Ronald
    Hamberg, Paul
    Meulenbeld, Hielke J.
    Beeker, Aart
    Creemers, Geert-Jan
    Martens, John W. M.
    Sleijfer, Stefan
    CANCERS, 2019, 11 (08)
  • [43] Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
    Mak, Blossom
    Lin, Hui-Ming
    Kwan, Edmond M.
    Fettke, Heidi
    Ben Tran
    Davis, Ian D.
    Mahon, Kate
    Stockler, Martin R.
    Briscoe, Karen
    Marx, Gavin
    Zhang, Alison
    Crumbaker, Megan
    Tan, Winston
    Huynh, Kevin
    Meikle, Thomas G.
    Mellett, Natalie A.
    Hoy, Andrew J.
    Du, Pan
    Yu, Jianjun
    Jia, Shidong
    Joshua, Anthony M.
    Waugh, David J.
    Butler, Lisa M.
    Kohli, Manish
    Meikle, Peter J.
    Azad, Arun A.
    Horvath, Lisa G.
    BMC MEDICINE, 2022, 20 (01)
  • [44] Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer
    Bitting, Rhonda L.
    Healy, Patrick
    Halabi, Susan
    George, Daniel J.
    Goodin, Michael
    Armstrong, Andrew J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (03) : 110.e1 - 110.e9
  • [45] Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
    Blossom Mak
    Hui-Ming Lin
    Edmond M. Kwan
    Heidi Fettke
    Ben Tran
    Ian D. Davis
    Kate Mahon
    Martin R. Stockler
    Karen Briscoe
    Gavin Marx
    Alison Zhang
    Megan Crumbaker
    Winston Tan
    Kevin Huynh
    Thomas G. Meikle
    Natalie A. Mellett
    Andrew J. Hoy
    Pan Du
    Jianjun Yu
    Shidong Jia
    Anthony M. Joshua
    David J. Waugh
    Lisa M. Butler
    Manish Kohli
    Peter J. Meikle
    Arun A. Azad
    Lisa G. Horvath
    BMC Medicine, 20
  • [46] Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer
    Han, Christopher Sejong
    Patel, Rutveej
    Kim, Isaac Yi
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (06) : 967 - 975
  • [47] Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer
    Dincman, Toros A.
    Karam, Joseph A. Q.
    Giordano, Antonio
    Li, Hong
    Drusbosky, Leylah M.
    Gourdin, Theodore S.
    Howe, Philip H.
    Lilly, Michael B.
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [48] Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
    Teo, Min Yuen
    Morris, Michael J.
    CANCER JOURNAL, 2016, 22 (05): : 347 - 352
  • [49] Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
    Adashek, Jacob J.
    Jain, Rohit K.
    Zhang, Jingsong
    CELLS, 2019, 8 (08)
  • [50] Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
    Zarrabi, Kevin K.
    Narayan, Vivek
    Mille, Patrick J.
    Zibelman, Matthew R.
    Miron, Benjamin
    Bashir, Babar
    Kelly, William Kevin
    THERAPEUTIC ADVANCES IN UROLOGY, 2023, 15
12345